このエントリーをはてなブックマークに追加
ID 55228
フルテキストURL
著者
Hiroshi, Umemura Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamasaki, Osamu Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaji, Tatsuya Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Otsuka, Masaki Division of Dermatology, Shizuoka Cancer Center Hospital
Asagoe, Kenji Department of Dermatology, National Hospital Organization Okayama Medical Center
Takata, Minoru Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwatsuki, Keiji Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0-II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III-IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.
キーワード
5-S-cysteinyl-dopa
biomarker
lactate dehydrogenase
malignant melanoma
serum 5-S-CD
備考
学位審査副論文
発行日
2017-04
出版物タイトル
Journal of Dermatology
44巻
4号
出版者
Wiley-Blackwell
開始ページ
449
終了ページ
454
ISSN
03852407
NCID
AA00696658
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン
author
PubMed ID
DOI
Web of Sience KeyUT
関連URL
isVersionOf https://doi.org/10.1111/1346-8138.13651